DecisionDx-GBM Gene Expression Assay for Prognostic Testing in Glioblastoma Multiform | Zendy

Diane AllinghamHawkins | Zendy; Andrew Lea | Zendy; Susan Levine | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

DecisionDx-GBM Gene Expression Assay for Prognostic Testing in Glioblastoma Multiform

Author(s) -

Diane AllinghamHawkins,

Andrew Lea,

Susan Levine

Publication year - 2010

Publication title -

plos currents

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.282

H-Index - 49

ISSN - 2157-3999

DOI - 10.1371/currents.rrn1186

Subject(s) - glioblastoma , medicine , glioma , oncology , brain tumor , overall survival , bioinformatics , gene , cancer research , pathology , biology , genetics

It is estimated that approximately 22,000 Americans will be diagnosed with tumor of the brain or nervous system in 2010. Among primary brain tumors, approximately 60% are gliomas, the most common and most malignant of which is glioblastoma multiforme (GBM).The DecisionDx-GBM test is a multigene expression assay that is designed to predict which patients are likely to experience long-term (> 2 years) progression-free survival.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research